The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang et al. used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and III IFN immunity. They found enrichment of these genes in patients and conclude that genetics may determine the clinical course of the infection. Bastard et al. identified individuals with high titers of neutralizing autoantibodies against type I IFN-α2 and IFN-ω in about 10% of patients with severe COVID-19 pneumonia. These autoantibodies were not found either in infected people who were asymptomatic or had milder phenotype or in healthy individuals. Together, these studies identify a means by which individuals at highest risk of life-threatening COVID-19 can be identified. Science , this issue p. [eabd4570], p. [eabd4585]; see also p.  ### INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (COVID-19). Epidemiological studies have identified three risk factors for severe disease: being male, being elderly, and having other medical conditions. However, interindividual clinical variability remains huge in each demographic category. Discovering the root cause and detailed molecular, cellular, and tissue- and body-level mechanisms underlying life-threatening COVID-19 is of the utmost biological and medical importance. ### RATIONALE We established the COVID Human Genetic Effort ([www.covidhge.com]) to test the general hypothesis that life-threatening COVID-19 in some or most patients may be caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance. We sequenced the exome or genome of 659 patients of various ancestries with life-threatening COVID-19 pneumonia and 534 subjects with asymptomatic or benign infection. We tested the specific hypothesis that inborn errors of Toll-like receptor 3 (TLR3)– and interferon regulatory factor 7 (IRF7)–dependent type I interferon (IFN) immunity that underlie life-threatening influenza pneumonia also underlie life-threatening COVID-19 pneumonia. We considered three loci identified as mutated in patients with life-threatening influenza: TLR3 , IRF7 , and IRF9 . We also considered 10 loci mutated in patients with other viral illnesses but directly connected to the three core genes conferring influenza susceptibility: TICAM1/TRIF , UNC93B1 , TRAF3 , TBK1 , IRF3 , and NEMO/IKBKG from the TLR3-dependent type I IFN induction pathway, and IFNAR1 , IFNAR2 , STAT1 , and STAT2 from the IRF7- and IRF9-dependent type I IFN amplification pathway. Finally, we considered various modes of inheritance at these 13 loci. ### RESULTS We found an enrichment in variants predicted to be loss-of-function (pLOF), with a minor allele frequency <0.001, at the 13 candidate loci in the 659 patients with life-threatening COVID-19 pneumonia relative to the 534 subjects with asymptomatic or benign infection ( P = 0.01). Experimental tests for all 118 rare nonsynonymous variants (including both pLOF and other variants) of these 13 genes found in patients with critical disease identified 23 patients (3.5%), aged 17 to 77 years, carrying 24 deleterious variants of eight genes. These variants underlie autosomal-recessive (AR) deficiencies ( IRF7 and IFNAR1 ) and autosomal-dominant (AD) deficiencies ( TLR3 , UNC93B1 , TICAM1 , TBK1 , IRF3 , IRF7 , IFNAR1 , and IFNAR2 ) in four and 19 patients, respectively. These patients had never been hospitalized for other life-threatening viral illness. Plasmacytoid dendritic cells from IRF7-deficient patients produced no type I IFN on infection with SARS-CoV-2, and TLR3−/−, TLR3+/−, IRF7−/−, and IFNAR1−/− fibroblasts were susceptible to SARS-CoV-2 infection in vitro. ### CONCLUSION At least 3.5% of patients with life-threatening COVID-19 pneumonia had known (AR IRF7 and IFNAR1 deficiencies or AD TLR3, TICAM1, TBK1, and IRF3 deficiencies) or new (AD UNC93B1, IRF7, IFNAR1, and IFNAR2 deficiencies) genetic defects at eight of the 13 candidate loci involved in the TLR3- and IRF7-dependent induction and amplification of type I IFNs. This discovery reveals essential roles for both the double-stranded RNA sensor TLR3 and type I IFN cell-intrinsic immunity in the control of SARS-CoV-2 infection. Type I IFN administration may be of therapeutic benefit in selected patients, at least early in the course of SARS-CoV-2 infection. ![Figure] Inborn errors of TLR3- and IRF7-dependent type I IFN production and amplification underlie life-threatening COVID-19 pneumonia. Molecules in red are encoded by core genes, deleterious variants of which underlie critical influenza pneumonia with incomplete penetrance, and deleterious variants of genes encoding biochemically related molecules in blue underlie other viral illnesses. Molecules represented in bold are encoded by genes with variants that also underlie critical COVID-19 pneumonia. Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)– and interferon regulatory factor 7 (IRF7)–dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection. : /lookup/doi/10.1126/science.abd4570 : /lookup/doi/10.1126/science.abd4585 : /lookup/doi/10.1126/science.abe7591 : https://www.covidhge.com : pending:yes
J.M.K. leads both clinical and research groups in the Department of Heart Rhythm Disorders at the Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia. He has an international reputation as a leader in the field of atrial arrhythmia research and has authored 380 peer-reviewed publications. He serves on the editorial board of 12 international cardiology journals and is an associate editor of JACC Clinical Electrophysiology. He is the immediate past president of the Asia Pacific Heart Rhythm Society and served as scientific chair of the Cardiac Society of Australia and New Zealand for 6 years. S.L. is Professor in Biochemistry & Molecular Biology at the Faculty of Chemical & Pharmaceutical Sciences and Professor in Cell & Molecular Biology in the Faculty of Medicine, University of Chile in Santiago, Chile and adjunct professor in the Cardiology Division, University of Texas Southwestern Medical Center in Dallas, USA.
Bakas, Spyridon, Reyes, Mauricio, Jakab, Andras, Bauer, Stefan, Rempfler, Markus, Crimi, Alessandro, Shinohara, Russell Takeshi, Berger, Christoph, Ha, Sung Min, Rozycki, Martin, Prastawa, Marcel, Alberts, Esther, Lipkova, Jana, Freymann, John, Kirby, Justin, Bilello, Michel, Fathallah-Shaykh, Hassan, Wiest, Roland, Kirschke, Jan, Wiestler, Benedikt, Colen, Rivka, Kotrotsou, Aikaterini, Lamontagne, Pamela, Marcus, Daniel, Milchenko, Mikhail, Nazeri, Arash, Weber, Marc-Andre, Mahajan, Abhishek, Baid, Ujjwal, Kwon, Dongjin, Agarwal, Manu, Alam, Mahbubul, Albiol, Alberto, Albiol, Antonio, Alex, Varghese, Tran, Tuan Anh, Arbel, Tal, Avery, Aaron, B., Pranjal, Banerjee, Subhashis, Batchelder, Thomas, Batmanghelich, Kayhan, Battistella, Enzo, Bendszus, Martin, Benson, Eze, Bernal, Jose, Biros, George, Cabezas, Mariano, Chandra, Siddhartha, Chang, Yi-Ju, Chazalon, Joseph, Chen, Shengcong, Chen, Wei, Chen, Jefferson, Cheng, Kun, Christoph, Meinel, Chylla, Roger, Clérigues, Albert, Costa, Anthony, Cui, Xiaomeng, Dai, Zhenzhen, Dai, Lutao, Deutsch, Eric, Ding, Changxing, Dong, Chao, Dudzik, Wojciech, Estienne, Théo, Shin, Hyung Eun, Everson, Richard, Fabrizio, Jonathan, Fang, Longwei, Feng, Xue, Fidon, Lucas, Fridman, Naomi, Fu, Huan, Fuentes, David, Gering, David G, Gao, Yaozong, Gates, Evan, Gholami, Amir, Gong, Mingming, González-Villá, Sandra, Pauloski, J. Gregory, Guan, Yuanfang, Guo, Sheng, Gupta, Sudeep, Thakur, Meenakshi H, Maier-Hein, Klaus H., Han, Woo-Sup, He, Huiguang, Hernández-Sabaté, Aura, Herrmann, Evelyn, Himthani, Naveen, Hsu, Winston, Hsu, Cheyu, Hu, Xiaojun, Hu, Xiaobin, Hu, Yan, Hu, Yifan, Hua, Rui, Huang, Teng-Yi, Huang, Weilin, Huo, Quan, HV, Vivek, Isensee, Fabian, Islam, Mobarakol, Albiol, Francisco J., Wang, Chiatse J., Jambawalikar, Sachin, Jose, V Jeya Maria, Jian, Weijian, Jin, Peter, Jungo, Alain, Nuechterlein, Nicholas K, Kao, Po-Yu, Kermi, Adel, Keutzer, Kurt, Khened, Mahendra, Kickingereder, Philipp, King, Nik, Knapp, Haley, Knecht, Urspeter, Kohli, Lisa, Kong, Deren, Kong, Xiangmao, Koppers, Simon, Kori, Avinash, Krishnamurthi, Ganapathy, Kumar, Piyush, Kushibar, Kaisar, Lachinov, Dmitrii, Lee, Joon, Lee, Chengen, Lee, Yuehchou, Lefkovits, Szidonia, Lefkovits, Laszlo, Li, Tengfei, Li, Hongwei, Li, Wenqi, Li, Hongyang, Li, Xiaochuan, Lin, Zheng-Shen, Lin, Fengming, Liu, Chang, Liu, Boqiang, Liu, Xiang, Liu, Mingyuan, Liu, Ju, Lladó, Xavier, Luo, Lin, Iftekharuddin, Khan M., Tsai, Yuhsiang M., Ma, Jun, Ma, Kai, Mackie, Thomas, Mahmoudi, Issam, Marcinkiewicz, Michal, McKinley, Richard, Mehta, Sachin, Mehta, Raghav, Meier, Raphael, Merhof, Dorit, Meyer, Craig, Mitra, Sushmita, Moiyadi, Aliasgar, Mrukwa, Grzegorz, Monteiro, Miguel A. B., Myronenko, Andriy, Carver, Eric N, Nalepa, Jakub, Ngo, Thuyen, Niu, Chen, Oermann, Eric, Oliveira, Arlindo, Oliver, Arnau, Ourselin, Sebastien, French, Andrew P., Pound, Michael P., Pridmore, Tony P., Serrano-Rubio, Juan Pablo, Paragios, Nikos, Paschke, Brad, Pei, Linmim, Peng, Suting, Pham, Bao, Piella, Gemma, Pillai, G. N., Piraud, Marie, Popli, Anmol, Prčkovska, Vesna, Puch, Santi, Puybareau, Élodie, Qiao, Xu, Suter, Yannick R, Scott, Matthew R., Rane, Swapnil, Rebsamen, Michael, Ren, Hongliang, Ren, Xuhua, Rezaei, Mina, Lorenzo, Pablo Ribalta, Rippel, Oliver, Robert, Charlotte, Choudhury, Ahana Roy, Jackson, Aaron S., Manjunath, B. S., Salem, Mostafa, Salvi, Joaquim, Sánchez, Irina, Schellingerhout, Dawid, Shboul, Zeina, Shen, Haipeng, Shen, Dinggang, Shenoy, Varun, Shi, Feng, Shu, Hai, Snyder, James, Han, Il Song, Soni, Mehul, Stawiaski, Jean, Subramanian, Shashank, Sun, Li, Sun, Roger, Sun, Jiawei, Sun, Kay, Sun, Yu, Sun, Guoxia, Sun, Shuang, Park, Moo Sung, Szilagyi, Laszlo, Talbar, Sanjay, Tao, Dacheng, Tao, Dacheng, Khadir, Mohamed Tarek, Thakur, Siddhesh, Tochon, Guillaume, Tran, Tuan, Tseng, Kuan-Lun, Turlapov, Vadim, Tustison, Nicholas, Shankar, B. Uma, Vakalopoulou, Maria, Valverde, Sergi, Vanguri, Rami, Vasiliev, Evgeny, Vercauteren, Tom, Vidyaratne, Lasitha, Vivekanandan, Ajeet, Wang, Guotai, Wang, Qian, Wang, Weichung, Wen, Ning, Wen, Xin, Weninger, Leon, Wick, Wolfgang, Wu, Shaocheng, Wu, Qiang, Xia, Yong, Xu, Yanwu, Xu, Xiaowen, Xu, Peiyuan, Yang, Tsai-Ling, Yang, Xiaoping, Yang, Hao-Yu, Yang, Junlin, Yang, Haojin, Yao, Hongdou, Young-Moxon, Brett, Yue, Xiangyu, Zhang, Songtao, Zhang, Angela, Zhang, Kun, Zhang, Xuejie, Zhang, Lichi, Zhang, Xiaoyue, Zhao, Sicheng, Zhao, Yu, Zheng, Yefeng, Zhong, Liming, Zhou, Chenhong, Zhou, Xiaobing, Zhu, Hongtu, Zong, Weiwei, Kalpathy-Cramer, Jayashree, Farahani, Keyvan, Davatzikos, Christos, van Leemput, Koen, Menze, Bjoern
Gliomas are the most common primary brain malignancies, with different degrees of aggressiveness, variable prognosis and various heterogeneous histologic sub-regions, i.e., peritumoral edematous/invaded tissue, necrotic core, active and non-enhancing core. This intrinsic heterogeneity is also portrayed in their radio-phenotype, as their sub-regions are depicted by varying intensity profiles disseminated across multi-parametric magnetic resonance imaging (mpMRI) scans, reflecting varying biological properties. Their heterogeneous shape, extent, and location are some of the factors that make these tumors difficult to resect, and in some cases inoperable. The amount of resected tumor is a factor also considered in longitudinal scans, when evaluating the apparent tumor for potential diagnosis of progression. Furthermore, there is mounting evidence that accurate segmentation of the various tumor sub-regions can offer the basis for quantitative image analysis towards prediction of patient overall survival. This study assesses the state-of-the-art machine learning (ML) methods used for brain tumor image analysis in mpMRI scans, during the last seven instances of the International Brain Tumor Segmentation (BraTS) challenge, i.e. 2012-2018. Specifically, we focus on i) evaluating segmentations of the various glioma sub-regions in pre-operative mpMRI scans, ii) assessing potential tumor progression by virtue of longitudinal growth of tumor sub-regions, beyond use of the RECIST criteria, and iii) predicting the overall survival from pre-operative mpMRI scans of patients that undergone gross total resection. Finally, we investigate the challenge of identifying the best ML algorithms for each of these tasks, considering that apart from being diverse on each instance of the challenge, the multi-institutional mpMRI BraTS dataset has also been a continuously evolving/growing dataset.
Our aim is to publish prioritized research from all over the world in terms of global health in the form of oral and summary papers without wasting time. All oral presentation sessions and conferences of the relevant month will be broadcast live on the 27th of each month on MedicReS scientific TV channel broadcasting 24 hours a day. In parallel with all the developments in technology, we delivered MedicReS 2022 Congress to all our members via MedicReS TV on our www.medicres.club Papers coming to our congress pass through the referee system in MedicReS advisory boards, and oral abstracts are published in English in MedicReS GMR World Congress Abstracts and Congress Proceedings Book. Your oral presentations are also given to you as MP4.
The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang et al. used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and III IFN immunity. They found enrichment of these genes in patients and conclude that genetics may determine the clinical course of the infection. Bastard et al. identified individuals with high titers of neutralizing autoantibodies against type I IFN-α2 and IFN-ω in about 10% of patients with severe COVID-19 pneumonia. These autoantibodies were not found either in infected people who were asymptomatic or had milder phenotype or in healthy individuals. Together, these studies identify a means by which individuals at highest risk of life-threatening COVID-19 can be identified. Science , this issue p. [eabd4570], p. [eabd4585]; see also p.  ### INTRODUCTION Interindividual clinical variability is vast in humans infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to rapid death. Three risk factors for life-threatening coronavirus disease 2019 (COVID-19) pneumonia have been identified—being male, being elderly, or having other medical conditions—but these risk factors cannot explain why critical disease remains relatively rare in any given epidemiological group. Given the rising toll of the COVID-19 pandemic in terms of morbidity and mortality, understanding the causes and mechanisms of life-threatening COVID-19 is crucial. ### RATIONALE B cell autoimmune infectious phenocopies of three inborn errors of cytokine immunity exist, in which neutralizing autoantibodies (auto-Abs) against interferon-γ (IFN-γ) (mycobacterial disease), interleukin-6 (IL-6) (staphylococcal disease), and IL-17A and IL-17F (mucocutaneous candidiasis) mimic the clinical phenotypes of germline mutations of the genes that encode the corresponding cytokines or receptors. Human inborn errors of type I IFNs underlie severe viral respiratory diseases. Neutralizing auto-Abs against type I IFNs, which have been found in patients with a few underlying noninfectious conditions, have not been unequivocally shown to underlie severe viral infections. While searching for inborn errors of type I IFN immunity in patients with life-threatening COVID-19 pneumonia, we also tested the hypothesis that neutralizing auto-Abs against type I IFNs may underlie critical COVID-19. We searched for auto-Abs against type I IFNs in 987 patients hospitalized for life-threatening COVID-19 pneumonia, 663 asymptomatic or mildly affected individuals infected with SARS-CoV-2, and 1227 healthy controls from whom samples were collected before the COVID-19 pandemic. ### RESULTS At least 101 of 987 patients (10.2%) with life-threatening COVID-19 pneumonia had neutralizing immunoglobulin G (IgG) auto-Abs against IFN-ω (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three individual type I IFNs. These auto-Abs neutralize high concentrations of the corresponding type I IFNs, including their ability to block SARS-CoV-2 infection in vitro. Moreover, all of the patients tested had low or undetectable serum IFN-α levels during acute disease. These auto-Abs were present before infection in the patients tested and were absent from 663 individuals with asymptomatic or mild SARS-CoV-2 infection ( P < 10−16). They were present in only 4 of 1227 (0.33%) healthy individuals ( P < 10−16) before the pandemic. The patients with auto-Abs were 25 to 87 years old (half were over 65) and of various ancestries. Notably, 95 of the 101 patients with auto-Abs were men (94%). ### CONCLUSION A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men. In these patients, adaptive autoimmunity impairs innate and intrinsic antiviral immunity. These findings provide a first explanation for the excess of men among patients with life-threatening COVID-19 and the increase in risk with age. They also provide a means of identifying individuals at risk of developing life-threatening COVID-19 and ensuring their enrolment in vaccine trials. Finally, they pave the way for prevention and treatment, including plasmapheresis, plasmablast depletion, and recombinant type I IFNs not targeted by the auto-Abs (e.g., IFN-β). ![Figure] Neutralizing auto-Abs to type I IFNs underlie life-threatening COVID-19 pneumonia. We tested the hypothesis that neutralizing auto-Abs against type I IFNs may underlie critical COVID-19 by impairing the binding of type I IFNs to their receptor and the activation of the downstream responsive pathway. Neutralizing auto-Abs are represented in red, and type I IFNs are represented in blue. In these patients, adaptive autoimmunity impairs innate and intrinsic antiviral immunity. ISGs, IFN-stimulated genes; TLR, Toll-like receptor; IFNAR, IFN-α/β receptor; pSTAT, phosphorylated signal transducers and activators of transcription; IRF, interferon regulatory factor. Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men. : /lookup/doi/10.1126/science.abd4570 : /lookup/doi/10.1126/science.abd4585 : /lookup/doi/10.1126/science.abe7591 : pending:yes